GUANGZHOU, China, Oct. 11, 2021 /PRNewswire/ -- The Twist Alliance Pan-Cancer Methylation Panel (Pan-Cancer Panel), a solution for pan-cancer study including DNA methylation library preparation and targeted enrichment for next-generation sequencing (NGS), was launched globally on September 24th (US time). The Pan-Cancer Panel was developed over a two-year period by AnchorDx in collaboration with Twist Bioscience (NASDAQ: TWST).
The Pan-Cancer Panel, coupled the DNA methylation markers that were discovered, curated and validated by AnchorDx from many large-scale clinical studies, with the superior panel design, high-quality DNA synthesis platform and the strict quality control process developed by Twist Bioscience, ensures robust and high-performance output for large-scale screening of patient samples. The panel covers 47 disease entities from The Cancer Genome Atlas (TCGA) and 31 cancer types, such as lung, breast and colorectal cancers, each is represented by ~1000 informative genomic regions.
"DNA methylation has become an increasingly important biomarker for early cancer detection. The identification of methylation by sequencing has been challenging due to low sensitivity and efficiency and high cost. We developed a unique target enrichment-based approach to make methylation detection significantly better," said Emily Leproust, Ph.D., CEO and Co-founder of Twist Bioscience. "Collaborating with AnchorDx, a leading early cancer detection company, to develop the pan-cancer methylation panel leverages AnchorDx's expertise in the cancer diagnostics field and enables wider access of the product and platform. We are pleased to bring the Twist Pan-Cancer Methylation Panel to the scientific community."
"The Twist Alliance Pan-Cancer Methylation Panel is a high-performance and cost-effective solution for comprehensive DNA methylation analysis. It shall facilitate basic cancer research and diagnostics development. With the launch of this product, we hope to make our due contribution to the global cancer screening efforts, and look forward to future collaborations with either academics or industries to develop more impactful clinical products." said Dr. Jian-Bing Fan, CEO and Founder of AnchorDx.
AnchorDx and Twist Bioscience signed an agreement to co-market the Twist Alliance Pan-Cancer Methylation Panel globally.
News from Twist:
Founded in 2015, AnchorDx is a world-leading developer of cancer screening and early detection solutions based on methylation NGS technology. AnchorDx strives to revolutionize single/multi/pan-cancer early screening, detection technologies, and products. The current product pipeline encompasses more than 70% of all cancers. In addition, AnchorDx has a proprietary database and artificial intelligence platform designed for early lung cancer screening, diagnosis, and treatment.
About Twist Bioscience
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including but not limited to the continued wide accessibility of the Pan-Cancer Panel, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; the retention of employees of acquired companies and the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits, risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience's patents or proprietary rights; and the risk that Twist Bioscience's proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience's business in general, see Twist Bioscience's risk factors set forth in Twist Bioscience's Quarterly Report Form 10-Q filed with the Securities and Exchange Commission on August 9, 2021 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
View original content to download multimedia:https://www.prnewswire.com/news-releases/twist-alliance-pan-cancer-methylation-panel-global-launch-event---a-strategic-collaboration-between-anchordx-and-twist-bioscience-for-pan-cancer-liquid-biopsy-301396510.html